We appreciate the letter from Castet et al.,1 which comments on our recently published study,2 ‘Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors,’ and presents an extended comparative analysis of the genomic profile of acquired resistance in patients with pancreatic ductal adenocarcinoma (PDAC) treated with either KRASG12C off-state inhibitors or the novel pan-RAS inhibitor, daraxonrasib.…
Mechanisms of genomic resistance across emerging classes of KRAS inhibitors
Annals of Oncology | | J.M. Riedl, R.B. Corcoran
Topics: pancreatic-cancer, blood-cancer, cervical-cancer, targeted-therapy, research